Threshold level of low-density lipoprotein cholesterol for the short-term benefit of statin therapy in the acute phase of myocardial infarction

Clinical Cardiology

Volumn 35, Issue 4, 2012, Pages 211-218

  Lee, Jang Hoon ^a   Park, Sun Hee ^a   Yang, Dong Heon ^a   Park, Hun Sik ^a   Cho, Yongkeun ^a   Lee, Won Kee ^a   Jeong, Myung Ho ^b   Kim, Young Jo ^c   Jun, Jae Eun ^a   Chae, Shung Chull ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Young Nam University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; DISEASE REGISTRY; DRUG EFFECT; FEMALE; HEART DEATH; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; REVASCULARIZATION;

AGED; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; CONFIDENCE INTERVALS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTRIES; REPUBLIC OF KOREA; TIME FACTORS;

EID: 84859749624     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20984     Document Type: Article

References (27)

1. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007; 49: 1272-1278.
2. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-1504.
3. Stenestrand U, Wallentin L., Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001; 285: 430-436.
4. Fonarow GC, Wright RS, Spencer FA, et al. National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005; 96: 611-616.
5. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285: 1711-1718.
6. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee [published correction appears in Circulation. 2008;117:e162]. Circulation. 2008; 117: 296-329.
7. Anderson JL, Adams CD, Antman EM, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/NonST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007; 116: e148-e304.
8. Grundy SM, Cleeman JI, Merz CN, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44: 720-732.
9. Karthikeyan G, Teo KK, Islam S, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. J Am Coll Cardiol. 2009; 53: 244-253.
10. Lee SR, Jeong MH, Ahn YK, et al. Korea Acute Myocardial Infarction Registry Investigators. Clinical safety of drug-eluting stents in the Korea Acute Myocardial Infarction Registry. Circ J. 2008; 72: 392-398.
11. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000; 21: 1502-1513.
12. Rosenbaum PR, Rubin DB., The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70: 41-55.
13. Law MR, Wald NJ, Thompson SG., By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994; 308: 367-372.
14. Schatz IJ, Masaki K, Yano K, et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet. 2001; 358: 351-355.
15. Horwich TB, Hamilton MA, Maclellan WR, et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002; 8: 216-224.
16. Behar S, Graff E, Reicher-, Reiss H, et al. Low total cholesterol is associated with high total mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Study Group. Eur Heart J. 1997; 18: 52-59.
17. Baigent C, Wheeler DC., Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure? Nephrol Dial Transplant. 2000; 15: 1118-1119.
18. Lefer AM, Campbell B, Shin YK, et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 1999; 100: 178-184.
19. Di Napoli P, Antonio Taccardi A, Grilli A, et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res. 2001; 51: 283-293.
20. Rosensen RS, Tangney CC., Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998; 279: 1643-1650.
21. Crisby M, Nordin-, Fredricksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001; 103: 926-933.
22. Notarbartolo A, Dav G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995; 15: 247-251.
23. Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of Endothelium) Trial. Circulation. 1999; 99: 3227-3233.
24. O'Driscoll G, Green D, Taylor RR., Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997; 95: 1126-1131.
25. Newby LK, Kristinsson A, Bhapkar MV, et al. SYMPHONY and 2nd SYMPHONY Investigators (Sibrafiban vs Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-acute Coronary Syndromes). Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA. 2002; 287: 3087-3095.
26. Cho YK, Hur SH, Han CD, et al. Comparison of ezetimibe/simvastatin 10/20 mg versus atorvastatin 20 mg in achieving a target low density lipoprotein-cholesterol goal for patients with very high risk. Korean Circ J. 2011; 41: 149-153.
27. Yun KH, Park HY, Choi JH, et al. Comparison of efficacy and safety after administering high potency statin to high risk patients: rosuvastatin 10 mg versus atorvastatin 20 mg. Korean Circ J. 2007; 37: 154-160.